Table 1.
Comparison of baseline demographics of patients with or without MVI
| MVI(+) | MVI(−) | p value | ||
|---|---|---|---|---|
| n = 204 | n = 458 | |||
| age > 60y | 37(18.1) | 135(29.5) | 0.002 | |
| Gender(male/female) | 19/185 | 72/386 | 0.028 | |
| Positive HBsAg | 186(91.2) | 390(85.2) | 0.034 | |
| Positive HBV-DNA load(>10^3 IU/ml) | 97(47.5) | 203(44.3) | 0.448 | |
| AFP(> 400 ng/ml) | 110(53.9) | 179(39.1)) | < 0.001 | |
| Differentiation | poor | 109(53.4) | 166(36.2) | < 0.001 |
| well-moderate | 95(46.6) | 292(63.8) | ||
| Satellite lesion | 49(24.0) | 37(8.1) | < 0.001 | |
| Tumor number** | one | 140(68.6) | 367(80.1) | < 0.001 |
| two | 27(13.2) | 62(13.5) | ||
| more | 37(18.1) | 29(6.3) | ||
| Tumor size(cm) | 7.9 ± 4.0 | 6.0 ± 3.3 | < 0.001* | |
| Ishak score | 5–6 | 139(68.1) | 285(62.2) | 0.161 |
| 0–4 | 65(31.9) | 173(37.8) | ||
| BCLC classification** | A | 144(70.6)) | 373(81.4) | 0.002 |
| B | 60(29.4) | 85(18.6) | ||
| Lg10ALT(U/l)) | 1.7 ± 0.3 | 1.6 ± 0.3 | 0.457 | |
| Lg10AST(U/l) | 1.7 ± 0.2 | 1.6 ± 0.3 | 0.007 | |
| ALB(g/l) | 41.4 ± 4.2 | 41.5 ± 4.4 | 0.928 | |
| TBIL(mmol/l) | 15.1 ± 7.2 | 15.1 ± 6.9 | 0.938 | |
| PLR | ≥111 | 87(42.6) | 146(31.9) | 0.008 |
| < 111 | 117(57.4) | 312(68.1) | ||
| NLR | ≥3 | 76(37.3) | 118(25.8) | 0.003 |
| < 3 | 128(62.7) | 340(74.2) | ||
| Surgery type | extend | 44(21.6) | 95(20.7) | 0.006 |
| major | 81(39.7) | 130(28.4) | ||
| minor | 79(38.7) | 233(50.9) | ||
| Blood transfusion | 22(10.8) | 28(6.1) | 0.039 | |
| Recurrence site | intra-hepatic | 142(69.6) | 238(52.0) | < 0.001 |
| extra-hepatic | 26(12.7) | 43(9.4) | ||
| Recurrence treatments | salvage LT | 1(0.5) | 7(1.5) | < 0.001 |
| re-resection | 15(7.4) | 33(7.2) | 0.066 | |
| radiofrequency ablation | 9(4.4) | 31(6.8) | < 0.001 | |
| TACE | 72(35.3) | 93(20.3) | < 0.001 | |
| pallitive therapy | 64(31.4) | 97(21.2) | < 0.001 |
*indicates statistically significant, **compared by the Mann–Whitney rank sum test
MVI microvascular invasion, HBsAg hepatitis B virus surface antigen, HBV-DNA hepatitis B viral DNA, AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, ALT alanine aminotransferase, AST aspartate aminotransferase, PLT Platelet, ALB albumin, TBIL total bilirubin, PLR platelet to lymphocyte ratio, NLR neutrophil to lymphocyte ratio, LT liver transplantation, TACE transarterial chemoembolization